Ketamine is a controlled substance that was approved as anesthetic by the FDA in 1970 and quickly became one of the most widely used anesthetics in the world. It has the ability to anesthetize patients quickly and safely with few side effects. Unlike many other anesthetics, ketamine does not depress patients’ breathing or circulatory systems, so it is commonly used on the battlefield and in environments without adequate monitoring equipment.
While every ketamine infusion clinic operates differently, treatment will generally begin with a consultation where you discuss your condition(s) and treatment history, complete assessments of the severity of your symptoms, review your treatment plan, undergo a brief physical exam, and discuss any other questions or concerns that weren’t answered in prior consultations with the clinic. At KetaMind, each individual session includes a ketamine infusion through an IV while you recline in a safe, quiet, relaxing environment with pillows, blankets, noise-cancelling headphones, calming music, and continuous monitoring of your vital signs and demeanor by a highly-trained and compassionate medical team.
Ketamine benefits vary depending upon your condition type and severity. In most cases, you’ll see a substantial improvement in your symptoms, usually 50% or greater, and sometimes even total relief. Most patients see improved mood and function after treatment and are better able to be social, excel at work, be physically active, get healthier nutrition, and improved quality of sleep.
For more than 20 years, ketamine-based treatments have become an increasingly popular solution for difficult to treat conditions, including treatment-resistant depression, suicidal thinking, post-traumatic stress disorder (PTSD), anxiety, obsessive-compulsive disorder (OCD), other mood disorders, Reflex Sympathetic Dystrophy (RSD), and other neuropathic conditions, although ketamine has not been approved by the regulatory authorities for these indications. Scientifically proven to work quickly and safely with substantial relief in over 50 clinical research studies at prestigious institutions, ketamine therapy has been called the biggest breakthrough treatment of its kind in 50 years.
The intravenous ketamine infusion therapy success rate is the highest because of the specific mechanism of action (how the body receives, processes, and is affected by the medicine) and the 100% bioavailability (how much medicine enters the bloodstream and can have an effect) that is only possible with the IV route of administration. This ketamine success rate has been proven to be much higher than ketamine administered by other methods as well as much higher than traditional prescription treatments, in some cases almost two and a half times higher. While there is some indication of other routes of administration (ways of getting the medicine) helping treat mood disorders, none of them have been proven as safe, effective, and fast-acting as the intravenous route.
At KetaMind, we focus exclusively on administering ketamine intravenously for the reasons listed above. We are an evidence-based practice that is motivated by science, continuity of care, and maximum therapeutic benefit for our patients.
More than 50 peer-reviewed clinical trials at leading medical institutions and universities have proven the efficacy of ketamine infusion therapy for depression, and other mood disorders. There are at least an additional 70 studies about ketamine’s tremendous impact on treating mood disorders underway. Most of these studies have singled out severe, treatment-resistant cases that have not responded to most of the conventional treatment options and they still report a success rate of around 70% or higher among patients.
Ketamine is one of only two anesthetics listed by the World Health Organization (WHO) as an “essential medicine.” The WHO is a specialized agency of the United Nations concerned with international public health. Their essential medicines are “those medicines that satisfy the health care needs of the majority of the population; they should, therefore, be available at all times in adequate amounts and in appropriate dosage forms, at a price the community can afford.” WHO’s essential medicines are the basis for many countries’ national drug policies.
Much of the early research on ketamine for depression and other mood disorders was based on a single infusion but that poses two main problems. First, many patients don’t respond to treatment until after their second or third infusion, while some require a full series of six before experiencing significant relief from their symptoms. This led to some patients being deemed “non-responders” when they might have responded well if they had additional treatment. The second problem is the relief for the “responders” was generally reported to last an average of 7-10 days with a single infusion, not accounting for the additional duration that multiple infusions can provide. This caused many early critics to say, “It works, but it doesn’t last.”
These findings inspired the care team at KetaMind to pioneer a series of six infusions over 2-3 weeks, each 55 minutes long, producing more pronounced and much longer-lasting benefits.